{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T23:42:58Z","timestamp":1773531778213,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MINECO","award":["SAF2017-83351-R and SAF 2014-52374-R"],"award-info":[{"award-number":["SAF2017-83351-R and SAF 2014-52374-R"]}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Raras","award":["U 707"],"award-info":[{"award-number":["U 707"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Von Hippel-Lindau syndrome (VHL) is a rare disease of dominant inheritance that increases susceptibility to tumor development, with a complete penetrance at the age of 60. In this report, we present the unprecedented case of a VHL carrier who remains healthy at 72. Under the course of this study, it was discovered that this patient carries a mutation for a second rare disease, Neuronal Ceroid Lipofuscinosis (NCL or CNL). We hypothesize that the <jats:italic>CLN<\/jats:italic> mutation she carries offers a protective effect, preventing tumor development in the cells potentially suffering a <jats:italic>VHL<\/jats:italic> second hit mutation. To test this hypothesis, we ran a series of molecular experiments and confirmed that cell viability of primary endothelial cells decreases upon <jats:italic>CLN5<\/jats:italic> silencing. Our results further elucidate the cell biology implications of two rare diseases interacting.<\/jats:p>","DOI":"10.1186\/s13023-020-01410-y","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T13:07:20Z","timestamp":1591103240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["CLN5 in heterozygosis may protect against the development of tumors in a VHL patient"],"prefix":"10.1186","volume":"15","author":[{"given":"Isabel","family":"de Rojas-P","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Albi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Recio-Poveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Rodriguez-Rufi\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel M.","family":"Cuesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-2245","authenticated-orcid":false,"given":"Luisa-Mar\u00eda","family":"Botella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"1410_CR1","unstructured":"2014 Report on the State of the Art of Rare Disease Activities in Europe. EUCERD Joint Action. European Comission. 2019. http:\/\/ec.europa.eu\/health\/rare_diseases\/. Accessed 10 Oct 2019."},{"key":"1410_CR2","unstructured":"Genetic and Rare Diseases Information Center. NIH, Gaithersburg, MD. 2019. http:\/\/rarediseases.info.nih.gov\/. Accessed 10 Oct 2019."},{"key":"1410_CR3","unstructured":"Rare diseases in numbers: preliminary report from an on going bibliographic study initiated by Eurordis in partnership with Orphanet. Orphanet Rare Disease Platform, Paris. 2018. https:\/\/www.orpha.net\/actor\/Orphanews\/2005\/doc\/Rare_Diseases_in_Numbers.pdf. Accessed 10 Oct 2019."},{"key":"1410_CR4","unstructured":"What Is a Rare Disease? EURORDIS Rare Diseases Europe. Fondation Universitaire, Brussels. 2007. https:\/\/www.eurordis.org\/content\/what-rare-disease. Accessed 10 Oct 2019."},{"key":"1410_CR5","first-page":"425","volume":"26","author":"DM Fanny Cort\u00e9s","year":"2015","unstructured":"Fanny Cort\u00e9s DM. Las Enfermedades Raras Rare Diseases. Cl\u00ednica Las Condes. 2015;26:425\u201331.","journal-title":"Cl\u00ednica Las Condes"},{"key":"1410_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cts.12500","volume":"11","author":"CP Austin","year":"2018","unstructured":"Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, Thomson D, Terry SF, de Montleau B, Ardig\u00f2 D, Hivert V, Boycott KM, Baynam G, et al. Future of rare diseases research 2017\u20132027: an IRDiRC perspective. Clin Transl Sci. 2018;11:21\u20137.","journal-title":"Clin Transl Sci"},{"key":"1410_CR7","first-page":"1","volume":"11","author":"D Lal","year":"2016","unstructured":"Lal D, Neubauer BA, Toliat MR, Altm\u00f6ller J, Thiele H, N\u00f6rnberg P, Kamrath C, Sch\u00e4nzer A, Sander T, Hahn A, Nothnagel M. Increased probability of co-occurrence of two rare diseases in consanguineous families and resolution of a complex phenotype by next generation sequencing. PLoS One. 2016;11:1\u201316.","journal-title":"PLoS One"},{"key":"1410_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/ajmg.1320310606","volume":"5","author":"JA Rider","year":"1988","unstructured":"Rider JA, Rider DL. Batten disease: past, present, and future. Am J Med Genet Suppl. 1988;5:21\u20136.","journal-title":"Am J Med Genet Suppl"},{"key":"1410_CR9","first-page":"2262","volume":"2015","author":"J Radke","year":"1852","unstructured":"Radke J, Stenzel W, Goebel HH. Human NCL neuropathology. Biochim Biophys Acta - Mol Basis Dis. 1852;2015:2262\u20136.","journal-title":"Biochim Biophys Acta - Mol Basis Dis."},{"key":"1410_CR10","first-page":"2237","volume":"2015","author":"SE Mole","year":"1852","unstructured":"Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (batten disease). Biochim Biophys Acta - Mol Basis Dis. 1852;2015:2237\u201341.","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"1410_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.beem.2010.01.002","volume":"24","author":"M Barontini","year":"2010","unstructured":"Barontini M, Dahia PLM. VHL disease. Best Pract Res Clin Endocrinol Metab. 2010;24:401\u201313.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1410_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher ER, Neumann HPH, Richard S. Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19:617\u201323.","journal-title":"Eur J Hum Genet"},{"key":"1410_CR13","first-page":"765","volume":"60","author":"AH Prowse","year":"1997","unstructured":"Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet. 1997;60:765\u201371.","journal-title":"Am J Hum Genet"},{"key":"1410_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc885","volume":"2","author":"WG Kaelin","year":"2002","unstructured":"Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673\u201382.","journal-title":"Nat Rev Cancer"},{"key":"1410_CR15","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","volume":"22","author":"WY Kim","year":"2004","unstructured":"Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991\u20135004.","journal-title":"J Clin Oncol"},{"key":"1410_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1399-0004.2009.01281.x","volume":"77","author":"MLM Poulsen","year":"2010","unstructured":"Poulsen MLM, Budtz-J\u00f8rgensen E, Bisgaard ML. Surveillance in von Hippel-Lindau disease (vHL). Clin Genet. 2010;77:49\u201359.","journal-title":"Clin Genet"},{"key":"1410_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","volume":"77","author":"ER Maher","year":"1990","unstructured":"Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA. Clinical features and natural history of von hippel-Lindau disease. Qjm. 1990;77:1151\u201363.","journal-title":"Qjm."},{"key":"1410_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/jmg.28.7.443","volume":"28","author":"ER Maher","year":"1991","unstructured":"Maher ER, Iselius L, ML JRWY, Benjamin C, Harris R, AW JS, NM MAF-S. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28:443\u20137.","journal-title":"J Med Genet"},{"key":"1410_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/molehr\/4.12.1099","volume":"4","author":"A Basu","year":"1998","unstructured":"Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod. 1998;4:1099\u2013109.","journal-title":"Mol Hum Reprod"},{"issue":"6","key":"1410_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/humu.20496","volume":"28","author":"A Gasc\u00f3n","year":"2007","unstructured":"Gasc\u00f3n A, Escobar B, Montero-Conde C, Rodr\u00edguez-Antona C, Ruiz-Llorente S, Osorio A, et al. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. Hum Mutat. 2007;28(6):613\u201321.","journal-title":"Hum Mutat"},{"key":"1410_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-015-0343-5","volume":"10","author":"V Albi\u00f1ana","year":"2015","unstructured":"Albi\u00f1ana V. Villar G\u00f3mez De Las Heras K, Serrano-Heras G, Segura T, Perona-Moratalla AB, Mota-P\u00e9rez M, De Campos JM, Botella LM. Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. Orphanet J Rare Dis. 2015;10:1\u201312.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01410-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01410-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01410-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:14:48Z","timestamp":1622592888000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01410-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01410-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All methods described in the present manuscript were carried out in accordance with all the international relevant guidelines and regulations of obliged fulfilment in the National Research Council of Spain (CSIC), and in agreement with worldwide regulations for Molecular Research, as also following the guidelines of the Declaration of Helsinki. A written informed consent was obtained from the patients prior to sample collection and publication of this case report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors critically reviewed the manuscript and approved the final manuscript as submitted and agree to be accountable for all aspects of the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}